言語を選択

EphA2

EphA2 詳細

英語名	Ephrin type-A receptor 2	市販薬剤の数	2
治験薬の数	9	ターゲットの別称	EC:2.7.10.1，Epithelial Cell Receptor Protein Tyrosine Kinase，Ephrin type-A receptor 2，Epithelial cell kinase，EPHA2，EPH Receptor A2，Tyrosine-Protein Kinase Receptor ECK，ECK，Soluble EPHA2 Variant 1，EC 2.7.10.1，CTRCT6，ARCC2，CTPP1，CTPA，Receptor， EphA2，EC 2.7.10
研究＆開発段階	Approved

英語名	Ephrin type-A receptor 2
ターゲットの別称	EC:2.7.10.1，Epithelial Cell Receptor Protein Tyrosine Kinase，Ephrin type-A receptor 2，Epithelial cell kinase，EPHA2，EPH Receptor A2，Tyrosine-Protein Kinase Receptor ECK，ECK，Soluble EPHA2 Variant 1，EC 2.7.10.1，CTRCT6，ARCC2，CTPP1，CTPA，Receptor， EphA2，EC 2.7.10
市販薬剤の数	2
治験薬の数	9
研究＆開発段階	Approved

EphA2 製品リスト

属性
Protein (3)
製品ライブラリ
オンライン (3)
種
Human (2)Rat (1)
タグ
His Tag (2)His Tag & Avi Tag (1)
マーカー
Unconjugated (2)Biotin-labeled (1)

製品番号	種	発現システム	製品説明
EP2-H52H4	Human	HEK293	Human EphA2 Protein, His Tag, low endotoxin (MALS verified)
EP2-H82E4	Human	HEK293	Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified)
EP2-R52H5	Rat	HEK293	Rat EphA2 Protein, His Tag (MALS verified)

総数量3

EphA2バックグランド

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.

EphA2分子の別称

EphA2

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
BT-5528	BT-5528; BT5528	Phase 2 Clinical	Bicycle Therapeutics	Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Head and Neck Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms	詳細
siRNA-EphA2-DOPC		Phase 1 Clinical	The University Of Texas MD Anderson Cancer Center	Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours	詳細
18F-Dasatinib	18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825	Phase 1 Clinical	Memorial Sloan Kettering Cancer Center	Bone Marrow Neoplasms; Carcinoma; Diagnostic agents; Lymphoma; Melanoma; Neoplasms; Sarcoma	詳細
E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine)		Phase 1 Clinical	University Of California San Francisco	Glioblastoma	詳細
SC-102	SC-102	Phase 1 Clinical	Tianjin Conjustar Biotechnology Co Ltd	Neoplasms; Solid tumours	詳細
EphA2-targeted CAR-DCs therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)		Phase 1 Clinical	Second Affiliated Hospital School Of Zhejiang University School Of Medicine	Carcinoma, Non-Small-Cell Lung	詳細
EphA2-targeted CAR-T Cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)		Phase 1 Clinical	Second Affiliated Hospital School Of Zhejiang University School Of Medicine	Carcinoma, Non-Small-Cell Lung	詳細
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)		Phase 1 Clinical	California Institute For Regenerative Medicine, National Cancer Institute	Glioblastoma	詳細
[18F]AlF-ETN	[18F]AlF-ETN	Phase 1 Clinical	Capital Medical University, Yunnan Baiyao Group Co Ltd	Prostatic Neoplasms; Solid tumours	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Regorafenib	DAST; BAY-73-4506	Approved	Bayer AG	Stivarga, Resihance	United States	Colorectal Neoplasms	Bayer Healthcare Pharmaceuticals Inc	2012-09-27	Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms	詳細
Dasatinib Hydrate	NSC-732517; BMS-354825	Approved	Bristol-Myers Squibb Company	Spraysel, 施达赛, Spricel, Sprycel	United States	Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic	Bristol-Myers Squibb Company	2006-06-28	Adenocarcinoma, Clear Cell; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Blast Crisis; Bone metastases; Brain Neoplasms; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Chondrosarcoma; Chordoma; Colonic Neoplasms; Coronavirus Disease 2019 (COVID-19); Cystadenocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumor of Bone; Glioblastoma; Glioma; Gliosarcoma; Heart Arrest; Hemangiopericytoma; Hematologic Neoplasms; HIV Infections; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypereosinophilic Syndrome; Hypopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Immunoproliferative Small Intestinal Disease; Intraocular Lymphoma; Laryngeal Diseases; Laryngeal Neoplasms; Leukemia; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myel	詳細